Development

Clinical and research tools for cancer and neurological disease

We build proprietary tools for single-cell physiology, neurologic applications, and advanced cell-based medical products for personalised medicine.

HybriCure®

An advanced cell-based product built with proprietary electrofusion technology. It consists of fused tumour and antigen-presenting cells.

Published in Clinical and Translational Medicine (CTM), Volume 11, Issue 8: doi.org/10.1002/ctm2.505

Request a status report at development@celicabiomedical.com

SmartCure® Glia

Patented SMART pharmacological agents that blunt pathological neuroglia responses. Target areas include cognitive disorders, tissue response to trauma, Alzheimer's disease, multiple sclerosis, and related conditions.

Request a status report at development@celicabiomedical.com

Research instrumentation

With partners we build instruments used for more than 15 years in labs worldwide. At the core is a patch-clamp amplifier with a built-in phase-sensitive lock-in.

Instruments

Patch-clamp amplifier with dual-phase lock-in and CELL software — SWAM 2C
Autoclavable electrofusion chamber in biocompatible materials
Isolation amplifiers ISO 6 / ISO 4 / ISO 2
Instrumentation amplifiers IA 6 / IA 4 / IA 2
Low-noise amplifiers LNA6 / LNA4 / LNA2
Square-wave stimulator DST8 / ST8
Electrocardiogram amplifier ECGA 1
Isolation unit IU10A

Software

CELL — acquisition and analysis of single-cell signals
ColocANA — automated colocalisation analysis
Particle TR — particle tracking and analysis
Particle CO — particle counting

References

National research programme “Cell Physiology”
Clinical trial of autologous hybridomas (EudraCT 2012-005498-29)
Partners: Slovenian Research Agency, Carl Zeiss Reference Centre, Lek (Sandoz)